Drug Profile
Exenatide biobetter - Dong-A Pharmaceutical
Alternative Names: DA-3091; Long-acting exenatideLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer Dong-A ST
- Class Antihyperglycaemics; Biobetters; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 01 Sep 2017 Discontinued - Phase-I for Type-2 diabetes mellitus in South Korea (SC)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in South Korea (SC, Injection)
- 01 Apr 2012 Dong-A Pharmaceutical completes a phase I trial in Type-2 diabetes mellitus (in volunteers) in South Korea (NCT01156779)